On 6th Aug, 2024, Taichung Veterans General Hospital (TCVGH) announced that it had signed an MOU with Boehringer Ingelheim to develop smart clinical trials for new drug research in six major specialties: pulmonary, cardio-renal-metabolic diseases, oncology, schizophrenia, immunology, and ophthalmology. This collaboration aims to optimize clinical trial processes, including participant screening, consent signing, home visits, and remote physiological data collection, to maximize innovative research capabilities. 

James Chiou, Managing Director at Boehringer Ingelheim Taiwan, emphasized that their previous collaborations with TVGH have focused on early-phase clinical trials in areas such as pulmonary fibrosis, cancer, and autoimmune diseases. TVGH has achieved top rankings in trial recruitment for pulmonary fibrosis, positioning itself among the top 3% of global trial centers. 

You can find more information here: https://news.gbimonthly.com/tw/article/show.php?num=70101

編輯推薦

• 中榮攜百靈佳殷格翰簽MOU 發展智慧臨床試驗助6專科新藥研發
• 長庚攜百靈佳殷格翰 簽臨床試驗MOU
• 中榮間質肺病整合照護中心 首創聯手逾8家醫院擴整合照護網絡
• 陳適安：成立「智慧醫療委員會」從Top down促台中榮總數位化轉型
• 成大醫院、百靈佳殷格翰簽臨床試驗MOU 拚增早期試驗數量